Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, Lizhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, Qiming; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xinhua; Wang, Yongsheng; Huang, Jian-An; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, Liping; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; Zhou, He; Fang, Jian; Gu, Kai; Dong, Xiaorong; Zhang, Tao; We, Shi; Zou, Jianjun

doi:10.1016/s2213-2600(20)30365-9

Cited by 342 publications

(379 citation statements)

References 24 publications

Supporting

Mentioning

357

Contrasting

Order By: Relevance

“…In the aspect of effectiveness indicators, we found that the ORR, PFS, CR value of combined treatment with camrelizumab were better than that of single-drug treatment, and the ORR, PFS, CR value of single-drug treatment with camrelizumab were better than that of chemotherapy. These results indicated that the combination therapy of camrelizumab was more effective than single drug or chemotherapy (8,(17)(18)(19).…”

Section: Discussionmentioning

confidence: 88%

“…The 19). The abovementioned results suggested that the combination of camrelizumab was better than monotherapy, and monotherapy was better than chemotherapy (Figure 2).…”

Section: Efficacy Analysismentioning

confidence: 92%

“…After the first study was excluded, the heterogeneity could meet the requirements. ORR, PFS, and CR were used as indicators (8,(17)(18)(19) for publication bias analysis. Egger's test was used for publication bias analysis.…”

Section: Heterogeneity and Risk Of Biasmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis meta-analysis compared the safety and efficacy of camrelizumab monotherapy and combination therapy, aiming to provide a reference for the clinical combined use of camrelizumab in the treatment of cancers and also provide a reference for the development of subsequent indications of camrelizumab.MethodsMeta-analysis was used to analyze the four eligible literatures. Primary endpoints of effectiveness index were objective response rate (ORR), progression-free survival (PFS), control rate (CR). Primary endpoint of safety index was rating of severity of adverse drug reactions (grades 1–5).ResultsThe ORR, PFS, and CR values of combined treatment with camrelizumab was better than alone treatment, camrelizumab alone was better than chemotherapy (RR = 0.45; 95% CI, 0.30–0.67; P < 0.001; RR = 1.63; 95% CI, 1.25–2.13; P < 0.001; RR = 0.73; 95% CI, 0.52–1.02; P<0.001). When grade > 2, the incidence rate of combined treatment and chemotherapy are higher than monotherapy (RR = 0.66; 95% CI, 0.51–0.86; P<0.001). In any grade, the safety of camrelizumab combination therapy was better than that of monotherapy, the safety of chemotherapy was better than camrelizumab plus chemotherapy.ConclusionIn terms of effectiveness, the combination of camrelizumab is better than monotherapy, and monotherapy is better than chemotherapy. In terms of safety, when the grade > 2, single use is better than combination therapy and chemotherapy. In any grade of adverse event, the safety of combined use of camrelizumab is better than that of single use, and the safety of chemotherapy is better than the combined use of camrelizumab plus chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 88%

“…The 19). The abovementioned results suggested that the combination of camrelizumab was better than monotherapy, and monotherapy was better than chemotherapy (Figure 2).…”

Section: Efficacy Analysismentioning

confidence: 92%

See 1 more Smart Citation

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In the COVID-19 pandemic, there is an ongoing debate on whether to endorse wearing face masks to reduce the spread of infection 64 . However, most health experts recommend mask use, which addresses the general preventive principle when the baseline risk is very high, and none of the established medical treatments, such as a vaccine and antiviral drugs, are available.…”

Section: Discussionmentioning

confidence: 99%

Prosocial behavior of wearing a mask during an epidemic: an evolutionary explanation

Kabir

Risa

Tanimoto

2021

Sci Rep

View full text Add to dashboard Cite

In the midst of the COVID-19 pandemic, with limited or no supplies of vaccines and treatments, people and policymakers seek easy to implement and cost-effective alternatives to combat the spread of infection during the pandemic. The practice of wearing a mask, which requires change in people’s usual behavior, may reduce disease transmission by preventing the virus spread from infectious to susceptible individuals. Wearing a mask may result in a public good game structure, where an individual does not want to wear a mask but desires that others wear it. This study develops and analyzes a new intervention game model that combines the mathematical models of epidemiology with evolutionary game theory. This approach quantifies how people use mask-wearing and related protecting behaviors that directly benefit the wearer and bring some advantage to other people during an epidemic. At each time-step, a suspected susceptible individual decides whether to wear a facemask, or not, due to a social learning process that accounts for the risk of infection and mask cost. Numerical results reveal a diverse and rich social dilemma structure that is hidden behind this mask-wearing dilemma. Our results highlight the sociological dimension of mask-wearing policy.

show abstract

“…In China, according to the ORIENT-11 study (NCT03607539), sintilimab has been approved as the first-line treatment for non-squamous NSCLC combined with pemetrexed and platinum chemotherapy. The Phase III trial (NCT03134872) ( 18 ) of SHR-1210 combined with pemetrexed and carboplatin in the treatment of non-squamous non-small cell lung cancer is also ongoing. Nevertheless, due to the tumor heterogeneity and the complexity of the tumor microenvironment (TME), the overall response rates to ICI therapy keep at low levels ( 19 ).…”

Section: Immune Checkpoints and Inhibitorsmentioning

confidence: 99%

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from the increase in the expression of pro-angiogenic factors, which is involved in the regulation of the function and migration of immune cells. Anti-angiogenic agents can normalize blood vessels, and thus transforming the tumor microenvironment from immunosuppressive to immune-supportive by increasing the infiltration and activation of immune cells. Therefore, the combination of immunotherapy with anti-angiogenesis is a promising strategy for cancer treatment. Here, we outline the current understanding of the mechanisms of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling in tumor immune escape and progression, and summarize the preclinical studies and current clinical data of the combination of ICB and anti-angiogenic drugs in the treatment of advanced NSCLC.

show abstract

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Cited by 342 publications

References 24 publications

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis

Prosocial behavior of wearing a mask during an epidemic: an evolutionary explanation

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About